ArticleBMC cancer2025
Prediction of one-year recurrence among breast cancer patients undergone surgery using artificial intelligence-based algorithms: a retrospective study on prognostic factors.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated Clinical-Molecular Risk Stratification in Diffuse Large B-Cell Lymphoma: Machine Learning Survival Analysis.JMIR medical informatics · 2026Article
- Deep Learning-Based Recurrence Prediction in HER2-Low Breast Cancer: Comparison of MRI-Alone, Clinicopathologic-Alone, and Combined Models.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimBreast cancer is highly prevalent, with an increasing trend in women globally. Although the survival of breast cancer is relatively high, the recurrence rate is also high, demanding effective predictive solutions to breast cancer prognosis among post-operative patients. So far, Artificial intelligence algorithms integrated with various clinical data have demonstrated potential predictive capability regarding breast cancer recurrence.
objectiveThis study aims to specifically conduct a predictive analysis of one-year recurrence of breast cancer by comparing and analyzing different machine learning and deep learning algorithms trained by structural prognostic data. MATERIALS AND
methodsThis retrospective study was carried out using one database, including 1156 post-operative breast cancer data from 30 January 2020 to 30 December 2022, in three clinical centers in Tehran City. The inclusion criteria were patients who had undergone at least one surgery, had at least one year of medical records, and did not have other conditions. The patients who were diagnosed with malignant BC and had undergone adjuvant therapies without surgery were excluded from the study. Twenty-three prognostic factors were utilized to train algorithms to establish prediction models for the one-year recurrence of breast cancer. The data were analyzed using univariate and adjusted correlation-based methods and chosen machine learning and deep learning algorithms. The discrimination, calibration, and clinical utility were leveraged to assess the algorithms' performance efficiency. The SHapley Additive exPlanations plot was generated to identify the prominent prognostic factors affecting the one-year recurrence of breast cancer.
resultsTotally, 445 relapsed and 711 non-relapsed cases were utilized in this study. Our empirical study showed that the random forest with a positive predictive value of 0.96, negative predictive value of 0.92, sensitivity of 0.92, specificity of 0.96, accuracy of 0.94, F-score of 0.94, area under the receiver operator characteristics curve of 0.919 was the best-performing model for predicting the breast cancer recurrence. As the analysis of SHapley Additive exPlanations indicated, the tumor grade, HER-2, and the number of lymph nodes involved were more significant predictors.
conclusionThe current study demonstrated the potential predictive power of the random forest for early predicting tumors among breast cancer patients who have undergone surgery and its utility in enhancing decision-making in clinical environments. It is crucial in promoting the prognosis, more effectively choosing therapies, augmenting post-operative breast cancer patients' survival, and controlling the limited healthcare resources. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.